CNSX:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free BOLT Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume71,500 shsAverage Volume18,200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Bolt Biotherapeutics alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Bolt Biotherapeutics Stock (CNSX:BOLT)Bolt Metals Corp., an exploration company, engages in the acquisition and exploration of mineral properties in Indonesia and Canada. Its flagship project is the Cyclops nickel-cobalt project covering an area of approximately 5,000 hectares located in Papua province, Indonesia. The company was formerly known as Pacific Rim Cobalt Corp. and changed its name to Bolt Metals Corp. in February 2020. Bolt Metals Corp. is headquartered in West Vancouver, Canada.Read More Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 BOLT Stock News HeadlinesMarch 25, 2024 | markets.businessinsider.comBolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy RecommendationFebruary 9, 2024 | benzinga.comVivo Opportunity Fund Holdings, L.P.'s Net WorthApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.December 27, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)November 20, 2023 | finance.yahoo.comIs Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?November 10, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 7, 2023 | finance.yahoo.comBolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceOctober 24, 2023 | markets.businessinsider.comBolt Biotherapeutics: Buy Rating Justified by Promising Clinical Results and Strong Financial OutlookApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.October 19, 2023 | markets.businessinsider.comBolt Biotherapeutics: First Patient Dosed In Clinical Trial Of BDC-3042October 18, 2023 | benzinga.comBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual MeetingOctober 18, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual MeetingOctober 16, 2023 | finance.yahoo.comBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023September 28, 2023 | markets.businessinsider.comBolt Biotherapeutics' BDC-1001 Gets FDA Orphan Drug Designation To Treat Gastric CancersSeptember 12, 2023 | finance.yahoo.comBolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042August 9, 2023 | finance.yahoo.comBolt Biotherapeutics Second Quarter 2023 Earnings: Misses ExpectationsAugust 8, 2023 | finance.yahoo.comBolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comBolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerJuly 31, 2023 | finance.yahoo.comBolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023July 19, 2023 | msn.comAfter COVID, a Continued Push for Diversity in Clinical TrialsJune 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Bolt Biotherapeutics (BOLT)May 30, 2023 | finance.yahoo.comBioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseasesMay 25, 2023 | finance.yahoo.comBolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual MeetingMay 12, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For May 12, 2023May 11, 2023 | finance.yahoo.comBolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMarch 30, 2023 | msn.comLooking Into Bolt Biotherapeutics's Return On Capital EmployedFebruary 28, 2023 | finance.yahoo.comBolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare ConferenceSee More Headlines Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCNSX SectorBasic Materials Industry Other Industrial Metals & Mining Sub-IndustryN/A Current SymbolCNSX:BOLT CUSIPN/A CIKN/A Webpacificrimcobalt.com Phone604-922-8272FaxN/AEmployees65Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Ranjeet Sundher (Age 58)President, CEO & Director Comp: $202.73kMr. Steven Edward Vanry C.F.A.CFA, CIM, CFO, Secretary & DirectorMr. Alwi NabilCountry Financial ControllerKey CompetitorsAclara ResourcesTSE:ARA.TOAmerican Shared Hospital ServicesCNSX:AMSCME GroupCNSX:CMEFOXCNSX:FOXInterra CopperCNSX:IMCXView All Competitors BOLT Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Intelsat (I), Associated British Foods (ABF), Chaarat Gold (CGH), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU). This page (CNSX:BOLT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
